Literature DB >> 22094585

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

E Traer, R MacKenzie, J Snead, A Agarwal, A M Eiring, T O'Hare, B J Druker, M W Deininger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22094585      PMCID： PMC3960073          DOI： 10.1038/leu.2011.325

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.

Authors:  X Sun; J E Layton; A Elefanty; G J Lieschke
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

Review 2.  Hematopoietic cytokine receptor signaling.

Authors:  S J Baker; S G Rane; E P Reddy
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).

Authors:  Ajoy K Samanta; Sandip N Chakraborty; Yan Wang; Ellen Schlette; E Premkumar Reddy; Ralph B Arlinghaus
Journal:  Genes Cancer       Date:  2010-04

5.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.

Authors:  A Pardanani; T Lasho; G Smith; C J Burns; E Fantino; A Tefferi
Journal:  Leukemia       Date:  2009-03-19       Impact factor: 11.528

6.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Authors:  W S Pear; J P Miller; L Xu; J C Pui; B Soffer; R C Quackenbush; A M Pendergast; R Bronson; J C Aster; M L Scott; D Baltimore
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

7.  Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes.

Authors:  B A Roecklein; B Torok-Storb
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

8.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

9.  Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.

Authors:  Heather G Jørgensen; Elaine K Allan; Niove E Jordanides; Joanne C Mountford; Tessa L Holyoake
Journal:  Blood       Date:  2007-01-09       Impact factor: 22.113

10.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Authors:  Mhairi Copland; Ashley Hamilton; Lucy J Elrick; Janet W Baird; Elaine K Allan; Niove Jordanides; Martin Barow; Joanne C Mountford; Tessa L Holyoake
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113
View more
  54 in total

1.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Targeting survival pathways in chronic myeloid leukaemia stem cells.

Authors:  A Sinclair; A L Latif; T L Holyoake
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

3.  Stem cell persistence in chronic myeloid leukemia.

Authors:  M Deininger
Journal:  Leuk Suppl       Date:  2012-08-09

Review 4.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

5.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

6.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

7.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

Review 8.  Minimal Residual Disease Eradication in CML: Does It Really Matter?

Authors:  Srinivas K Tantravahi; Raga S Guthula; Thomas O'Hare; Michael W Deininger
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

9.  Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.

Authors:  J G Harb; P Neviani; B J Chyla; J J Ellis; G J Ferenchak; J J Oaks; C J Walker; P Hokland; D C Roy; M A Caligiuri; G Marcucci; C S Huettner; D Perrotti
Journal:  Leukemia       Date:  2013-05-14       Impact factor: 11.528

10.  MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.

Authors:  Jennifer Asmussen; Elisabeth A Lasater; Cheryl Tajon; Juan Oses-Prieto; Young-Wook Jun; Barry S Taylor; Alma Burlingame; Charles S Craik; Neil P Shah
Journal:  Cancer Discov       Date:  2013-12-20       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.